Price
$7.97-18.09%Social Signal Score
Analyst Ratings
11 analystsRevenue
$20.16M-4.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason Kelly
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 485
- Beta
- 1.77
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -8.59
Financials
Revenue
$20.16M-4.6%Net Income
$-46.71MEBITDA
$-44.36MFree Cash Flow
$-46.89MEPS (diluted)
$-0.75Shares Outstanding (diluted)
62.09M+103.9%Operating Expenses
$76.98MCash & Debt
$302.16MReturn of Capital
$0.00Revenue by Segment (annual)
$37.41MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $170.16M | $-312.76M | $-5.64 |
| 2024 | $227.04M | $-547.03M | $-10.54 |
| 2023 | $251.46M | $-892.87M | $-18.37 |
| 2022 | $477.71M | $-2.10B | $-50.15 |
| 2021 | $313.84M | $-1.83B | $-53.83 |
| 2020 | $76.66M | $-126.61M | $-3.97 |
| 2019 | $54.18M | $-119.33M | $-4.15 |
Valuation
DNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (7)
- Newszacks.com·4d ago·Negative
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.
View source ↗ - Newsglobenewswire.com·12d ago·Negative
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel
View source ↗ - Newszacks.com·12d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
View source ↗ - Newszacks.com·17d ago·Positive
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newszacks.com·19d ago·Neutral
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
DNA X, Inc. Reports Second Quarter 2026 Financial Results - Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Ginkgo Bioworks Q2 Earnings Call Highlights Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.58 per share
Typical surprise -14.8% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.75 vs $-0.90beat
- Thu, May 7$-1.39 vs $-1.21miss
- Thu, Feb 26$-1.42 vs $-1.80beat
- Thu, Nov 6$-1.45 vs $-1.24miss
- Thu, Aug 7$-1.10 vs $-1.44beat
- Tue, May 6$-1.68 vs $-1.23miss
Estimates and results for DNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DNA officers and directors.
- Bought
- —
- Sold
- $3.9m
0 trades
23 trades
- Henry Christian Osold
- Coen Steven P.sold
- Coen Steven P.sold
- Coen Steven P.sold
- Coen Steven P.sold
- Coen Steven P.sold
- Canton Barrysold
- Shetty Reshma P.sold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DNA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.